<DOC>
	<DOCNO>NCT00002919</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow surgery treat patient stage II bladder cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Stage II Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy combination chemotherapy methotrexate , vinblastine , doxorubicin , cisplatin ( MVAC ) follow aggressive transurethral resection bladder tumor patient stage II transitional cell carcinoma bladder without nuclear overexpression mutant p53 . II . Determine proportion patient treat regimen bladder preservation rather radical cystectomy possible . OUTLINE : All patient undergo complete near complete transurethral resection bladder tumor entry within 6 week prior entry . Upon confirmation stag histology , patient receive combination chemotherapy methotrexate , vinblastine , doxorubicin , cisplatin ( MVAC ) every 21 day 4 course . Subcutaneous G-CSF give course . Patients complete response chemotherapy proceed intravesical therapy observation ; partial response , stable disease , progression proceed definitive surgery . PROJECTED ACCRUAL : 30 patient enter approximately 18 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Invasive transitional cell carcinoma bladder clinical stage T23a N0 M0 cystoscopy Cystoscopy perform Memorial SloanKettering Cancer Center ( MSKCC ) No multifocal carcinoma situ No obstructive uropathy palpable mass Pathologic confirmation histology 20 % positive expression nuclear p53 , follow : On study follow transurethral resection bladder ( TURB ) OR At TURB perform within 6 week entry part initial stag PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60 % 100 % Hematopoietic : WBC least 3,500 Platelets great 150,000 Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 60 mL/min per 1.73 square meter Cardiovascular : No NYHA class III/IV status Other : No concomitant malignancy basal cell skin carcinoma Negative pregnancy test require fertile woman Adequate contraception require fertile woman PRIOR CONCURRENT THERAPY : No prior systemic chemotherapy No prior bladder irradiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage II bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>